The MEDS Act takes important steps toward ending the drug shortage crisis we are experiencing today, ASCO Board of Directors member Peter C. Adamson, MD stated during a briefing on Capitol Hill. Dr. Adamson spoke in support of Senate bill S. 2723, “The Mitigating Emergency Drug Shortages (MEDS) Act,” at the November 5 briefing.
In addition to serving on ASCO’s Board, Dr. Adamson is Chair of the Children’s Oncology Group, President of the Children’s Oncology Group Foundation, and a Professor of Pediatrics and Pharmacology at Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania. During the briefing, he discussed the unnecessary burden that shortages have on families who are already fighting pediatric cancer. Dr. Adamson also emphasized how shortages are preventable and that shortages in the United States are due in part to economic factors that other countries do not experience.
ASCO also sent a letter supporting the bill to its sponsors, Senators Susan Collins (R-ME) and Tina Smith (D-ME). The letter stated, “The MEDS Act builds upon the prior work of Congress to provide additional authority to the FDA to help mitigate drug shortages and develop market-based incentives to help ensure a stable supply of medications critical for patient care.”
Stay tuned to ASCO in Action for updates on this and other cancer policy developments.